an overall in-hospital mortality of 7.2% (7 of 97). Follow-up data were obtained from all patients, and the mean follow-up time was 43.36 25.5 months. The 5-year survival rate by Kaplan-Meier analysis was 86. 6%. Three patients with type I endoleak was successfully resolved during the operation. No endograft caudal migration occurred. Late aortic rupture was found in two patients, and two patients received reoperations during the follow-up period. No postoperative paraplegia was found.
Objectives: This study was conducted to evaluate outcomes of fenestrated-branched endovascular aneurysm repair (F-BEVAR) to treat pararenal (PR) and thoracoabdominal (TAAA) aneurysms performed in highrisk patients and to identify those patients likely to benefit from this treatment.
Methods: We performed a prospective single-center study of patients treated electively for PR and TAAA repair using F-BEVAR between 2005 and 2016. Survival was estimated with the Kaplan-Meier method. The risk factors associated with 30-day mortality and mortality during follow-up were determined using multivariate statistical techniques with a Cox regression model including all variables that were significant on univariate analysis (P < .05).
Results: We analyzed the data from 468 patients (median age, 71.6 years) with American Society for Anesthesiology score of III or IV. There were 221 (47.2%) type 1 to 3 TAAAs and 247 (52.8%) type 4 and PR aneurysms, with a median diameter of 60 mm. Technical success of target vessel stenting was 98.7 % (1497 of 1516). The 30-day mortality rate was 4.9% (23 patients). The spinal cord ischaemia rate was 3.8% (18 patients). Objectives: Biomarker (s) for the prediction of future progression of abdominal aortic aneurysms (AAA) may be useful to stratify the management of individual patients. AAAs are associated with features of systemic inflammation and endothelial dysfunction. Flow-mediated forearm brachial artery dilatation (FMD) is a recognized noninvasive measurement for endothelial function. We hypothesize that FMD is a potential biomarker of AAA progression and reflects the temporal changes of endothelial function during AAA progression.
Methods: In a prospectively recruited cohort of patients with AAAs (Oxford Abdominal Aortic Aneurysm Study), AAA size was recorded by anteroposterior (AP) diameter (outer to outer) on ultrasound imaging. Annual AAA progression was calculated by DAP diameter/ (number of days lapsed/365 days). FMD was assessed at the same time points throughout the natural history of AAA progression. Analyses of data were performed in the overall cohort and further in subgroups of AAAs by size (small: 30-39 mm; moderate: 40-55 mm; large: >55 mm).
Results: FMD is inversely correlated with the size of AAAs in all patients (n ¼ 162). There is significant reduction of FMD across the subgroups of AAA (Kruskal-Wallis test, P < .001; Fig 1, A) . FMD is predictive of AAA size progression in the future 12 months (Spearman r ¼ e0.41, P < .001; Fig 1, B) , particularly in the moderately sized group. Further, FMD deteriorates during the course of AAA surveillance (from a median of 2.0% at baseline to 1.2% at follow-up; P < .005, Fig 2) , while surgical repair of AAA (n ¼ 50; [open repair n ¼ 22, endovascular repair n ¼ 28]) leads to improvement in FMD (from 1.1% preoperatively to 3.8% postoperatively; P < .0001, Fig 2) , irrespective of the type of surgery.
Conclusions: FMD is inversely correlated with future AAA progression in humans. FMD deteriorates during the natural history of AAA and is improved by surgery. FMD may be an adjunctive measurement to AP diameter to better inform the frequency of surveillance and timing of surgery, particularly in patients with moderately sized AAAs. The utility of FMD as a biomarker for AAA progression warrants further validation. 
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